The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies.
S. Sharma
Research Funding - Millennium
R. Kurzrock
No relevant relationships to disclose
L. Gouw
No relevant relationships to disclose
D. S. Hong
No relevant relationships to disclose
K. Jones
No relevant relationships to disclose
X. Zhou
Employment or Leadership Position - Millennium
H. Shi
Employment or Leadership Position - Millennium
H. Fingert
Employment or Leadership Position - Millennium
G. S. Falchook
Research Funding - Millennium